NYSE - Nasdaq Real Time Price USD
Merck & Co., Inc. (MRK)
79.20
+0.16
+(0.20%)
As of 1:45:54 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
63.92B
64.17B
60.12B
59.28B
48.70B
Cost of Revenue
15.07B
15.19B
16.13B
17.41B
13.63B
Gross Profit
48.85B
48.98B
43.99B
41.87B
35.08B
Operating Expense
28.45B
28.75B
41.03B
23.59B
21.88B
Operating Income
20.40B
20.22B
2.95B
18.28B
13.20B
Net Non Operating Interest Income Expense
-830.00M
-856.00M
-781.00M
-805.00M
-770.00M
Other Income Expense
601.00M
571.00M
-284.00M
-1.03B
1.45B
Pretax Income
20.17B
19.94B
1.89B
16.44B
13.88B
Tax Provision
2.72B
2.80B
1.51B
1.92B
1.52B
Net Income Common Stockholders
17.43B
17.12B
365.00M
14.52B
13.05B
Diluted NI Available to Com Stockholders
17.43B
17.12B
365.00M
14.52B
13.05B
Basic EPS
6.90
6.77
0.14
5.73
5.16
Diluted EPS
6.88
6.74
0.14
5.71
5.14
Basic Average Shares
2.52B
2.53B
2.61B
2.53B
2.53B
Diluted Average Shares
2.54B
2.54B
2.61B
2.54B
2.54B
Total Expenses
43.52B
43.95B
57.16B
41.00B
35.51B
Net Income from Continuing & Discontinued Operation
17.43B
17.12B
365.00M
14.52B
13.05B
Normalized Income
17.89B
17.57B
861.91M
16.28B
12.17B
Interest Income
451.00M
415.00M
365.00M
157.00M
36.00M
Interest Expense
1.28B
1.27B
1.15B
962.00M
806.00M
Net Interest Income
-830.00M
-856.00M
-781.00M
-805.00M
-770.00M
EBIT
21.45B
21.21B
3.04B
17.41B
14.69B
EBITDA
26.06B
25.71B
6.91B
21.32B
17.90B
Reconciled Cost of Revenue
15.07B
15.19B
16.13B
17.41B
13.63B
Reconciled Depreciation
4.61B
4.50B
3.87B
3.91B
3.21B
Net Income from Continuing Operation Net Minority Interest
17.43B
17.12B
365.00M
14.52B
13.05B
Total Unusual Items Excluding Goodwill
-528.00M
-522.00M
-629.00M
-1.99B
982.00M
Total Unusual Items
-528.00M
-522.00M
-629.00M
-1.99B
982.00M
Normalized EBITDA
26.59B
26.23B
7.54B
23.31B
16.92B
Tax Rate for Calcs
0.13
0.14
0.21
0.12
0.11
Tax Effect of Unusual Items
-71.15M
-73.60M
-132.09M
-233.18M
107.62M
12/31/2021 - 1/2/1962
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BMY Bristol-Myers Squibb Company
47.67
+0.21%
PFE Pfizer Inc.
22.85
-0.15%
JNJ Johnson & Johnson
157.66
+2.06%
ABBV AbbVie Inc.
189.53
+1.27%
AMGN Amgen Inc.
275.37
+1.82%
OGN Organon & Co.
8.88
-2.74%
NVO Novo Nordisk A/S
67.20
+1.37%
LLY Eli Lilly and Company
780.47
+0.69%
GILD Gilead Sciences, Inc.
99.09
+1.24%
GSK GSK plc
37.14
-0.96%